ARNA Genomics is an innovative biotechnological company, launched on the basis of the
scientific and research laboratory and a team of like-minded people, engaged in development and research of early detection methods of oncological diseases with the purpose of launch of diagnostic tests for early cancer detection on the global market.
Our mission is to increase the life expectancy and significantly reduce human mortality by means of global market launch of most recent, unique in efficiency methods of screening (screening study with the purpose of detection and prevention of disease development in population), diagnostics (correct diagnosing) and monitoring of treatment process of oncological diseases.
ARNA Genomics company has discovered a technology which allows to develop tests for different types (nosologies) of cancer. Besides, the company has also developed a unique concept of blockchain based ecosystem, which will be used as an instrument to support R&D and implementation of biotechnologies worldwide.
We have completed R&D for the first product based on our technology – breast cancer test.
Colon cancer test is currently in R&D stage. Besides, we are currently developing a blockchain platform solution – ARNA Panacea, which will soon allow to change the world by making launch of new biotech solutions against cancer much easier and faster.